Episodes

Before COVID-19 hit, telehealth was breaking some ground, but it really took off with the pandemic and is becoming increasingly important part of dermatological practices. Telehealth brings both challenges and advantages for Dermatologists. To explore how to work telehealth to your advantage, Dr Kirk Barber talks with three experts in this field; Dr. Harvey Lui is Professor of Dermatology at the University of British Columbia, Dr Regine Mydlarski is Associate Professor of Dermatology at the Univ...

Post-inflammatory hyperpigmentation (PIH), when the skin becomes discolored or darkened, is a common consequence for people of color receiving laser treatments. It's a major challenge for Dermatologists and one with no clear solutions. Dr Vincent Richer of Pacific Derm in Vancouver, joins Kirk to discuss the article he co-authored with Dr. Ian Wong in the Jan/Feb 2021 issue of the Journal of Cutaneous Medicine and Surgery, "Prophylaxis of Post-Inflammatory Hyperpigmentation From Energy-Based Dev...

Post-inflammatory hyperpigmentation (PIH), when the skin becomes discolored or darkened, is a common consequence for people of color receiving laser treatments. It's a major challenge for Dermatologists and one with no clear solutions. Dr Vincent Richer of Pacific Derm in Vancouver, joins Kirk to discuss the article he co-authored with Dr. Ian Wong in the Jan/Feb 2021 issue of the Journal of Cutaneous Medicine and Surgery, "Prophylaxis of Post-Inflammatory Hyperpigmentation From Energy-Based Dev...

Post-inflammatory hyperpigmentation (PIH), when the skin becomes discolored or darkened, is a common consequence for people of color receiving laser treatments. It's a major challenge for Dermatologists and one with no clear solutions. Dr Vincent Richer of Pacific Derm in Vancouver, joins Kirk to discuss the article he co-authored with Dr. Ian Wong in the Jan/Feb 2021 issue of the Journal of Cutaneous Medicine and Surgery, "Prophylaxis of Post-Inflammatory Hyperpigmentation From Energy-Based Dev...

"When I was starting to use Dupilumab in my patients, I thought they were getting more positive results than what I would have expected. When I was seeing patients three or four months after being on treatment they were ecstatic, the were like 'Wow, this is really life changing.'" Dr Jensen Yeung returns to the JCMS Author Interviews podcast to talk to Kirk Barber about his article, "Short-Term Evaluation of the Real-World Efficacy and Safety of Dupilumab for the Treatment of Moderate-to-Severe...

"When I was starting to use Dupilumab in my patients, I thought they were getting more positive results than what I would have expected. When I was seeing patients three or four months after being on treatment they were ecstatic, the were like 'Wow, this is really life changing.'" Dr Jensen Yeung returns to the JCMS Author Interviews podcast to talk to Kirk Barber about his article, "Short-Term Evaluation of the Real-World Efficacy and Safety of Dupilumab for the Treatment of Moderate-to-Severe...

"When I was starting to use Dupilumab in my patients, I thought they were getting more positive results than what I would have expected. When I was seeing patients three or four months after being on treatment they were ecstatic, the were like 'Wow, this is really life changing.'" Dr Jensen Yeung returns to the JCMS Author Interviews podcast to talk to Kirk Barber about his article, "Short-Term Evaluation of the Real-World Efficacy and Safety of Dupilumab for the Treatment of Moderate-to-Severe...

"There really is no safety risk with any non-live vaccine to our patients on biologics. And the vast majority of studies state that the efficacy of vaccines is maintained for patients on biologic therapy." In a timely interview, Dr Mark Kirchhoff joins JCMS Editor in Chief Kirk Barber to discuss the impact of the rollout of COVID-19 vaccines on Dermatology patients, including a look at what vaccines are approved or will be approved in the near future, what immunotherapies are used in dermatolog...

"There really is no safety risk with any non-live vaccine to our patients on biologics. And the vast majority of studies state that the efficacy of vaccines is maintained for patients on biologic therapy." In a timely interview, Dr Mark Kirchhoff joins JCMS Editor in Chief Kirk Barber to discuss the impact of the rollout of COVID-19 vaccines on Dermatology patients, including a look at what vaccines are approved or will be approved in the near future, what immunotherapies are used in dermatolog...

"There really is no safety risk with any non-live vaccine to our patients on biologics. And the vast majority of studies state that the efficacy of vaccines is maintained for patients on biologic therapy." In a timely interview, Dr Mark Kirchhoff joins JCMS Editor in Chief Kirk Barber to discuss the impact of the rollout of COVID-19 vaccines on Dermatology patients, including a look at what vaccines are approved or will be approved in the near future, what immunotherapies are used in dermatolog...

Severity measurement scales for atopic dermatitis are important in clinical trials as objective outcome measures and they are often required for government and private insurance plans. These scales are sometimes underused by clinicians for a number of reasons, including time constraints and lack familiarity. Dr Patrick Fleming joins Dr Kirk Barber, editor-in-chief of the Journal of Cutaneous Medicine and Surgery, to talk about his article in the July/August edition of the Journal, reviewing the ...

Severity measurement scales for atopic dermatitis are important in clinical trials as objective outcome measures and they are often required for government and private insurance plans. These scales are sometimes underused by clinicians for a number of reasons, including time constraints and lack familiarity. Dr Patrick Fleming joins Dr Kirk Barber, editor-in-chief of the Journal of Cutaneous Medicine and Surgery, to talk about his article in the July/August edition of the Journal, reviewing the ...

Severity measurement scales for atopic dermatitis are important in clinical trials as objective outcome measures and they are often required for government and private insurance plans. These scales are sometimes underused by clinicians for a number of reasons, including time constraints and lack familiarity. Dr Patrick Fleming joins Dr Kirk Barber, editor-in-chief of the Journal of Cutaneous Medicine and Surgery, to talk about his article in the July/August edition of the Journal, reviewing the ...

In this special edition of JCMS Author Interviews, Kirk Barber, Editor-in-Chief of the Journal of Cutaneous Medicine and Surgery talks with Dr Jensen Yeung, about his article, "Management of Plaque Psoriasis with Biologics in Women of Childbearing Potential," in the special July/August supplement edition of JCMS. With women making up fifty percent of Psoriasis patients, what does published data reveal about the safety of treating pregnant and breastfeeding women with biologics? Listen and learn ...

In this special edition of JCMS Author Interviews, Kirk Barber, Editor-in-Chief of the Journal of Cutaneous Medicine and Surgery talks with Dr Jensen Yeung, about his article, "Management of Plaque Psoriasis with Biologics in Women of Childbearing Potential," in the special July/August supplement edition of JCMS. With women making up fifty percent of Psoriasis patients, what does published data reveal about the safety of treating pregnant and breastfeeding women with biologics? Listen and learn ...

In this special edition of JCMS Author Interviews, Kirk Barber, Editor-in-Chief of the Journal of Cutaneous Medicine and Surgery talks with Dr Jensen Yeung, about his article, "Management of Plaque Psoriasis with Biologics in Women of Childbearing Potential," in the special July/August supplement edition of JCMS. With women making up fifty percent of Psoriasis patients, what does published data reveal about the safety of treating pregnant and breastfeeding women with biologics? Listen and learn ...

"A lot of us have had patients with PRP who went on a biologic and they cleared quite rapidly and were very happy afterwards." Dr Patrick Fleming joins Kirk Barber, JCMS editor-in-chief, to discuss his article in the Jan/Feb 2020 issue of the journal, titled: “Use of Biologics in Pityriasis Rubra Pilaris Refractory to First-Line Systemic Therapy: A Systematic Review.“ Dr Patrick Fleming talks about how there has been an increasing number of studies reporting the successful use of biologicthera...

"A lot of us have had patients with PRP who went on a biologic and they cleared quite rapidly and were very happy afterwards." Dr Patrick Fleming joins Kirk Barber, JCMS editor-in-chief, to discuss his article in the Jan/Feb 2020 issue of the journal, titled: “Use of Biologics in Pityriasis Rubra Pilaris Refractory to First-Line Systemic Therapy: A Systematic Review.“ Dr Patrick Fleming talks about how there has been an increasing number of studies reporting the successful use of biologicthera...

"A lot of us have had patients with PRP who went on a biologic and they cleared quite rapidly and were very happy afterwards." Dr Patrick Fleming joins Kirk Barber, JCMS editor-in-chief, to discuss his article in the Jan/Feb 2020 issue of the journal, titled: “Use of Biologics in Pityriasis Rubra Pilaris Refractory to First-Line Systemic Therapy: A Systematic Review.“ Dr Patrick Fleming talks about how there has been an increasing number of studies reporting the successful use of biologicthera...

Dr Catherine McCuaig joins Dr Kirk Barber, Editor-in-Chief of the Journal of Cutaneous Medicine and Surgery, for a fascinating discussion about her article in the July/August edition of the Journal. It is a retrospective single-centre study of children with IBD under anti-TNF treatment between 2013 and 2016. Forty patients with CSE related to anti-TNF were referred to Dr McCuaig's pediatric dermatology clinic. A control group was randomly selected from patients receiving anti-TNF for IBD, who we...

Dr Catherine McCuaig joins Dr Kirk Barber, Editor-in-Chief of the Journal of Cutaneous Medicine and Surgery, for a fascinating discussion about her article in the July/August edition of the Journal. It is a retrospective single-centre study of children with IBD under anti-TNF treatment between 2013 and 2016. Forty patients with CSE related to anti-TNF were referred to Dr McCuaig's pediatric dermatology clinic. A control group was randomly selected from patients receiving anti-TNF for IBD, who we...

Dr Catherine McCuaig joins Dr Kirk Barber, Editor-in-Chief of the Journal of Cutaneous Medicine and Surgery, for a fascinating discussion about her article in the July/August edition of the Journal. It is a retrospective single-centre study of children with IBD under anti-TNF treatment between 2013 and 2016. Forty patients with CSE related to anti-TNF were referred to Dr McCuaig's pediatric dermatology clinic. A control group was randomly selected from patients receiving anti-TNF for IBD, who we...

Dr Regine Mydlarski joins Kirk Barber, Editor in Chief of the Journal of Cutaneous Medicine, for a fascinating snapshot of what Canadian Dermatology looks like today and what changes need to be made to meet the evolving needs of patients across Canada. As Chair of the Dermatology Working Group at the Royal College of Physicians and Surgeons of Canada, Dr Mydlarski led a comprehensive and objective analysis of the state of dermatology in Canada. This resulted in two articles in the JCMS, one in 2...

Dr Regine Mydlarski joins Kirk Barber, Editor in Chief of the Journal of Cutaneous Medicine, for a fascinating snapshot of what Canadian Dermatology looks like today and what changes need to be made to meet the evolving needs of patients across Canada. As Chair of the Dermatology Working Group at the Royal College of Physicians and Surgeons of Canada, Dr Mydlarski led a comprehensive and objective analysis of the state of dermatology in Canada. This resulted in two articles in the JCMS, one in 2...